BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,240,819 | -14.4% | 71,133 | +20.7% | 0.01% | -31.6% |
| Q2 2022 | $3,784,000 | -46.8% | 58,912 | -35.8% | 0.02% | -32.1% |
| Q1 2022 | $7,111,000 | +27.7% | 91,705 | +41.3% | 0.03% | +33.3% |
| Q4 2021 | $5,570,000 | -34.3% | 64,887 | -38.4% | 0.02% | -46.2% |
| Q3 2021 | $8,479,000 | -17.6% | 105,421 | -17.5% | 0.04% | -13.3% |
| Q2 2021 | $10,291,000 | +1027.2% | 127,838 | +1081.2% | 0.04% | +1025.0% |
| Q1 2021 | $913,000 | +11.2% | 10,823 | +5.7% | 0.00% | 0.0% |
| Q4 2020 | $821,000 | -0.2% | 10,238 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $823,000 | -48.6% | 10,238 | -45.0% | 0.00% | -50.0% |
| Q2 2020 | $1,602,000 | +184.0% | 18,609 | +168.0% | 0.01% | +100.0% |
| Q1 2020 | $564,000 | +78.5% | 6,944 | +83.8% | 0.00% | +100.0% |
| Q4 2019 | $316,000 | -99.5% | 3,779 | -99.5% | 0.00% | -99.4% |
| Q3 2019 | $62,103,000 | -33.5% | 709,997 | -37.7% | 0.34% | -32.9% |
| Q2 2019 | $93,398,000 | -11.0% | 1,140,393 | -11.6% | 0.50% | -14.1% |
| Q1 2019 | $104,933,000 | +18.9% | 1,290,532 | -3.8% | 0.58% | +6.4% |
| Q4 2018 | $88,284,000 | -14.7% | 1,341,302 | -0.1% | 0.55% | +1.1% |
| Q3 2018 | $103,470,000 | +7.9% | 1,342,202 | +3.4% | 0.54% | +2.1% |
| Q2 2018 | $95,870,000 | +4.1% | 1,298,342 | -8.3% | 0.53% | +1.7% |
| Q1 2018 | $92,107,000 | -34.2% | 1,416,159 | -34.6% | 0.52% | -31.7% |
| Q4 2017 | $139,918,000 | -3.4% | 2,164,569 | -6.2% | 0.76% | -8.5% |
| Q3 2017 | $144,846,000 | +4.5% | 2,308,299 | +0.9% | 0.84% | -3.9% |
| Q2 2017 | $138,554,000 | +28.2% | 2,288,630 | +9.8% | 0.87% | +10.4% |
| Q1 2017 | $108,074,000 | +252.9% | 2,083,954 | +201.7% | 0.79% | +227.9% |
| Q4 2016 | $30,623,000 | -6.8% | 690,633 | +0.1% | 0.24% | -12.4% |
| Q3 2016 | $32,843,000 | +19.8% | 689,984 | +13.8% | 0.27% | +17.6% |
| Q2 2016 | $27,408,000 | +647.6% | 606,104 | +579.2% | 0.23% | +606.1% |
| Q1 2016 | $3,666,000 | +1543.9% | 89,241 | +1428.6% | 0.03% | +1550.0% |
| Q4 2015 | $223,000 | -97.1% | 5,838 | -94.7% | 0.00% | -97.2% |
| Q2 2015 | $7,739,000 | -27.5% | 110,662 | -29.0% | 0.07% | -26.5% |
| Q1 2015 | $10,678,000 | -33.4% | 155,885 | -28.7% | 0.10% | -33.3% |
| Q4 2014 | $16,025,000 | +60.7% | 218,654 | +57.4% | 0.15% | +22.5% |
| Q3 2014 | $9,971,000 | +8.6% | 138,927 | +9.4% | 0.12% | +36.4% |
| Q2 2014 | $9,179,000 | +13.8% | 126,952 | +15.8% | 0.09% | 0.0% |
| Q1 2014 | $8,066,000 | +2.0% | 109,622 | -3.6% | 0.09% | 0.0% |
| Q4 2013 | $7,907,000 | +4.5% | 113,687 | -1.3% | 0.09% | -5.4% |
| Q3 2013 | $7,563,000 | +0.6% | 115,137 | +6.1% | 0.09% | -12.3% |
| Q2 2013 | $7,518,000 | – | 108,529 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |